Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

magazine

Will Hikma deliver good news concerning its generics business?

Look for an update when half year results are published on 17 August
Thursday 10 Aug 2017 Author: Lisa-Marie Janes
Week Ahead

Thursday 17 August

FTSE 250 stock Hikma Pharmaceuticals (HIK) has had a difficult year after the launch of its generic version of GlaxoSmithKline’s (GSK) Advair Diskus was delayed and full year earnings guidance was downgraded in May.

Investors should look for updates about when the launch could happen and whether the traditional oral generics business is improving when Hikma reports half year results on 17 August.

 

‹ Previous2017-08-10Next ›


10 Aug 2017

Download PDF

Page flip version

Important information:

These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.

Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.

Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.

The Shares team
Disclaimer

Issue contents

Big News

Editor's View

Feature

Funds

Great Ideas

Great Ideas Update

Investment Trusts

Larger Companies

Main Feature

Money Matters

Smaller Companies

Story In Numbers

Talking Point

Week Ahead

Magazine archive


31 Jul 2025
24 Jul 2025
17 Jul 2025

10 Jul 2025
3 Jul 2025
26 Jun 2025

19 Jun 2025
12 Jun 2025
5 Jun 2025